Allograft Adipose Injectable for Vocal Fold Paralysis

Vocal Fold Palsy Clinical Trial

Official title:

Safety and Efficacy of Allograft Adipose Matrix Injectable for Glottal Insufficiency

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04700566
• Other study ID #: HS-19-00876
• Status: Recruiting
• Phase: Phase 3
• Start date: May 16, 2022
• Est. completion date: July 1, 2025

Study information

• Verified date: February 2023
• Source: University of Southern California
• Contact: Karla O'Dell, MD
• Phone: 18008722273
• Email: karla.odell[@]med.usc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Renuva is allograft adipose matrix commonly used as a filler in cosmetic procedures. The investigators are studying this material as an injectable in the vocal fold to treat glottic insufficiency. Currently, many products can be used as an injectable in the vocal fold to correct glottic insufficiency such as carbomethycellulose, hyaluronic acid, collagen derivatives and calcium hydroxyapatite amongst others. An ideal injectable would not impair the fibroelastic property of the vocal fold tissues and would integrate within the tissue of the vocal fold. Since Renuva has the property of stimulating adipogenesis by using growth factor and collagen, the investigators believe it could represent a good option in terms of safety and efficacy for vocal fold augmentation. This study will assess the safety and efficacy of Renuva as a vocal fold injectable to treat glottic insufficiency.

Description:

Background/Significance: Vocal cord injection augmentation is commonly used to treat glottal insufficiency. Various materials are used for injection augmentation including autologous fat, hyaluronic acid, collagen, carboxymethylcellulose, and calcium hydroxyapatite. However, all of the current injection choices have individual limitations such as temporary effect, unpredictability due to variable resorption by the body, unfavorable mechanical properties, and challenging handling attributes. Hence, there is a need for a more ideal injection augmentation substance that is biocompatible, nonimmunogenic, able to traverse small gauge needles, easy to use, and facilitates long term or permanent effect when desired. Intervention: Unilateral injection augmentation with allograft adipose matrix injectable. Renuva ®, is commonly used as in injectable material in plastic surgery for treatment of small cosmetic irregularities. The injectable stimulates adipogenesis using key matrix proteins including collagen IV, collagen VI, FGF-2, and VEGF. The injectable does not contain any lipids, cellular fragments, or DNA content. In vitro and in vivo demonstrate that the injectable can stimulate adipose tissue generation. Given this important quality, allograft adipose matrix may provide vocal fold bulk for a longer period of time with favorable viscoelastic properties which would make it a desirable agent for vocal fold augmentation. Objective: Assess the safety profile and efficacy of allograft adipose matrix for use in injection augmentation Study Design: Single arm prospective clinical trial. Methods: 50 patients with glottal insufficiency will be enrolled to receive vocal fold augmentation injection using an Allograft adipose matrix, commercially available as Renuva ® over a 24 months recruitment period. Study endpoints: Primary study endpoint will be the completion of 12 months of follow up post injection with safety monitoring. Secondary endpoints will include patient reported outcome measures (VHI, VFI, DI and EAT-10), blinded Cape-V voice assessment by experts and laryngeal videostroboscopy blinded assessment with the mVali tool. Plan for analysis: The study cohort will be analyzed via descriptive statistics of the primary outcome (safety) via incidence of both minor and major adverse events. Non-parametric statistics (Wilcoxon signed-rank test) will be used for comparisons of patient reported outcome measures and blinded evaluations of voice and videostroboscopy endpoints from post-intervention time points to pre-intervention baseline.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: July 1, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• • Age = 18 years old
• Unilateral vocal fold immobility with glottal insufficiency present for at least 2 weeks from onset
• Willingness to partake in study and follow-up as documented by signed informed consent

Exclusion Criteria:

• History of allergy/hypersensitivity to lidocaine or amide-based anesthetics
• Pregnancy
• Active infection or inflammation in the larynx (presence of acute laryngeal infection caused by bacteria/virus or fungus)
• Comorbid known laryngeal conditions including but not limited to vocal fold scar, vocal tremor, laryngeal dystonia, etc. that would warrant other interventions for optimal treatment
• History of laryngeal surgery
• Life expectancy of less than 6 months

Related Conditions & MeSH terms

• Vocal Cord Paralysis
• Vocal Fold Palsy

Intervention

Biological:
• Renuva Allograft Adipose Matrix
Injection of Renuva Allograft adipose Matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency

Locations

Country	Name	City	State
United States	University of Southern California	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
University of Southern California

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of adverse recorded in participants after injection	Monitoring of adverse events during the study period for each participant receiving a vocal fold injection with Renuva	18 months
Secondary	Voice outcomes as reported by patient questionnaire	Voice Handicap Index (VHI-10) patient questionnaire at 0, 1, 3, 6, 12, and 18 months	18 months
Secondary	Score on VALI - Voice Vibratory Assessment of laryngeal imaging	Physician assessment of the stroboscopic examination (blinded) using the VALI scaleat day 0, and post injection 1, 3, 6, 12, and 18 months	18 months
Secondary	Dyspnea Index as measured by patient questionnaire	Dyspnea index questionnaired, filled at 0, 1months, 3 months, 6 months, 12 months, 18 months	18 months